Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 16,970	$ 4,024
Receivables	35	59
Prepaid expenses and other current assets	760	820
Total current assets	17,765	4,903
Property and equipment, net	9	64
Other non-current assets	149	12
Total assets	17,923	4,979
Current liabilities:
Accounts payable	4,039	6,186
Accrued expenses and other current liabilities	4,173	3,335
Deferred revenue	226	455
Total current liabilities	8,438	9,976
Warrant liability	176	1,773
Deferred revenue, non-current	3,922	4,091
Total liabilities	12,536	15,840
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.01 par value, 5,000,000 authorized at December 31, 2018 and 2017, none issued and outstanding at December 31, 2018 and 2017
Common stock, $0.01 par value, 250,000,000 and 25,000,000 authorized at December 31, 2018 and 2017, 5,674,220 and 718,078 shares issued and outstanding at December 31, 2018 and 2017	57	8
Additional paid in capital	387,238	350,614
Accumulated other comprehensive (loss) income	(12)	3
Accumulated deficit	(381,896)	(362,316)
Total Onconova Therapeutics, Inc. stockholders' equity (deficit)	5,387	(11,691)
Non-controlling interest		830
Total stockholders' equity (deficit)	5,387	(10,861)
Total liabilities and stockholders' equity (deficit)	$ 17,923	$ 4,979